Role of ferroptosis-related genes in prognostic prediction and tumor immune microenvironment in colorectal carcinoma

Chao Yang, Shuoyang Huang, Fengyu Cao and Yongbin Zheng
Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, China

ABSTRACT

Background and Aim. Colorectal cancer (CRC) ranks the second most common cause of cancer-related mortality worldwide. Ferroptosis, a recently discovered form of programmed cell death different from other, raises promising novel opportunities for therapeutic intervention of CRC. This study intended to systematically assess the prognosis value and multiple roles of the ferroptosis-related genes in the tumor immune microenvironment of CRC.

Materials and Methods. Of 1,192 CRC patients with complete information from the public datasets (TCGA CRC, GEO GSE39582 and GSE17538 cohorts) were selected for analysis. Firstly, K-means consensus clustering was performed to identify ferroptosis-associated subtypes in CRC patients. Subsequently, we constructed a risk signature based on ferroptosis-related genes in TCGA cohort and acquired its validation in two GEO cohorts. Additionally, we established a nomogram integrating the risk signature and clinical factors to improve risk assessment of CRC patients.

Results. Five molecular subtypes were identified by consensus clustering for ferroptosis-related genes. There were significant differences in the overall survival, immune cells infiltration status and PD1/PD-L1 mRNA among the five clusters. Then, a risk signature based on the ten-gene was constructed which could distinguish effectively high-risk group among CRC patients in both training and validation sets. The high-risk patients were more likely to have an inhibitory immune microenvironment and lower stemness features. A prognostic nomogram integrated risk signature and clinicopathological features could be used as a more accurate prognostic prediction visualization tool than TNM stage alone.

Conclusion. This ferroptosis risk signature may accurately differentiate between different risk populations and predict the prognosis of CRC. Besides, this study elucidated the crucial role of ferroptosis in tumor immune microenvironment.

INTRODUCTION

Colorectal cancer (CRC) ranks third in terms of incidence among malignancies and is the second most common cause of cancer-related mortality worldwide (Dekker et al., 2019). As
the most common gastrointestinal malignancy, CRC is associated with some well-known risk factors, including poor dietary patterns, obesity, alcoholic abuse, smoking and physical inactivity (Keum & Giovannucci, 2019). Besides environmental influences, divergent genomic factors also attribute to the complexity of CRC (Oines et al., 2017). Moreover, it is shown that the modality and mortality of CRC vary dramatically across different regions and countries, maybe due to socioeconomic factors (Carr et al., 2018). With the high-level heterogeneity, CRC presents huge difficulty in its prevention, early detection and treatment. Therefore, comprehensive and accurate risk assessment are particularly critical for diagnosis and surveillance of CRC. Currently, the approaches of risk assessment and monitoring of CRC depend largely on clinical features and pathological parameters. Tumor-node-metastasis (TNM) staging system is the most widely-used risk assessment tool (Weiser, 2018). Nevertheless, the current TNM staging system presents notable limitations in dealing with prognostic prediction on such a highly heterogeneous disease. Transcriptome profiling was extensively used in characterizing prognostic signatures of CRC patients, and obtained favorable effect in clinical application (Wang et al., 2020; Tokunaga et al., 2020). Hence, a robust prognostic genomic-clinico-pathologic signature may contribute to more accurate individualized survival prediction.

Ferroptosis is a recently discovered form of programmed cell death characterized as iron-dependent accumulation of lethal lipid peroxidation (Tang et al., 2018; Mou et al., 2019). There is a fundamental difference in molecular mechanism between ferroptosis and other cell death, including apoptosis, necrosis and autophagy (Gao et al., 2016). Ferroptosis is morphologically manifest by smaller mitochondria with condensed membrane and reduced or vanished cristae (Dong et al., 2019; Park & Chung, 2019). Increasing evidences show that ferroptosis serves a crucial role in cancer cell death among various cancer types including CRC (Chen et al., 2020; Guo et al., 2018). Some small molecule inducers of ferroptosis, including, Erastin, Sulfasalazine, FIN56 and Sorafenib, showed promising outcomes of anti-tumor treatment especially in some chemoresistance conditions (Liang et al., 2019). Apart from ferroptosis inducers, numerous genes also have been identified as modulators or markers of ferroptosis (Zhou et al., 2020). Previous studies reported that enhanced expression of HMOX1 was found involved in Erastin-induced ferroptosis and up-regulation of GCLM also contributed to the promotion of ferroptosis in CRC (Sharma et al., 2020). Furthermore, ferroptosis mediated by HO-1 hyper-expression was interrogated in a human colon cancer cell line (Malfa et al., 2019). On the contrary, the well-known tumor suppressor gene P53 was related to the downregulation of metabolic stress-induced ferroptosis (Kang, Kroemer & Tang, 2019). Both apoptosis evasion and enhancement of anti-apoptotic ability are considered to be important mechanisms of chemotherapy resistance in CRC (Hu et al., 2016; Mohammad et al., 2015). As a programmed cell death method completely differs from apoptosis, ferroptosis is expected to provide new hope for tumor treatment. Previous studies have reported prognostic models based on key gene expression profiles, which provide valuable supplementary information for the TNM staging system (Tokunaga et al., 2020). Nevertheless, the role of ferroptosis-related genes (FRGs) in prognostic prediction and tumor microenvironment remains largely unknown.
This study intended to systematically assess the prognosis value and multiple roles of the FRGs in the tumor immune microenvironment. In the study, we downloaded mRNA expression profiles and clinical data of CRC patients from public databases, the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). FRGs-associated subtypes in CRC patients were identified to improve prognostic risk stratification by K-means consensus clustering. Subsequently, we constructed a risk signature based on FRGs in TCGA cohort and acquired its validation in two GEO cohorts. Additionally, we established a nomogram integrating the risk signature and clinical factors to ameliorate prognostic assessment of CRC patients. This study also provided insights into the immune landscape and stemness feature among different risk groups. Collectively, this FRGs signature and nomogram might provide effective prediction tool and insight into novel potential intervention strategies for CRC.

MATERIALS AND METHODS

Data acquisition
The flow chart of this study is shown in Fig. 1. In training set, the level 3 RNA sequencing (RNA-seq) and matched clinical data of patients with CRC were downloaded from TCGA CRC cohort (https://portal.gdc.cancer.gov/repository). In validation set, the raw CEL data and corresponding clinical features of CRC patients were obtained from GEO GSE39582 and GSE17538 cohorts (https://www.ncbi.nlm.nih.gov/geo/).

The exclusion criteria of this study were set as follows: (1) Patients without complete clinical information. (2) Patients whose clinical follow-up time were less than 30 days. Consequently, 481 cases (437 tumor and 44 normal samples) conforming to the criteria were included in the training group, 542 cases (523 tumor and 19 normal samples) in GSE39582 and 238 cases (232 tumor and six normal samples) in the GSE17538 cohort (Supplementary table1). The FPKM format of RNA-seq data from TCGA cohort was converted into log2(TPM+1) for normalized counts. The robust multi-array average (RMA) algorithm was employed to normalize the raw data from GEO cohorts by the affy R package (Gautier et al., 2004). Both TCGA and GEO databases are publicly available, thus ethical approval is not required for present study.

Identification of FRGs
FerrDb is an online database containing information about regulators and markers of ferroptosis-related diseases (Zhou & Bao, 2020). A total of 214 FRGs that have been verified in homo sapiens were downloaded from FerrDb. The expression data of 200 FRGs were eventually matched in the TCGA and GEO cohorts for subsequent analysis (Table S2).

Establishment of the risk signature
The differentially expressed genes (DEGs) between tumor and adjacent normal tissues were identified in TCGA cohort with a false discovery rate (FDR) <0.05 using limma R package (Ritchie et al., 2015). Then, the univariate Cox analysis was used to find out FRGs with prognostic value among DEGs. Then STRING database was employed to
build an interaction network of those DEGs (http://string-db.org/). Afterwards, LASSO Cox regression analysis was performed to construct a prognostic model with minimizing the risk of overfitting. Variables selection were processed through LASSO algorithm by glmnet R package (Engebretsen & Bohlin, 2019). The risk score of the patients is calculated according to the normalized expression level of each gene and corresponding regression coefficient. The formula is established as follows: $\text{Risk Score} = \sum \beta \times \text{ExpFRGs}$. (where $\beta$ is the coefficient of FRGs and Exp is the expression level of the FRGs).

**Estimation of the risk signature for patient prognosis**

The CRC patients were classified into high- and low-risk groups according to the median value of the risk score. Survival curves between two groups were drawn by the survival and survminer R packages and compared with the Log-Rank test. Then, the area under the curves (AUCs) of time-dependent receiver operating characteristic (ROC) curves were calculated for predicting 1-year, 3-year and 5-year overall survival (OS). To exploration whether the risk signature could be used as an independent factor of OS in CRC, univariate and multivariate Cox regression analysis were performed. The relationship between the risk score and clinicopathological features was analyzed by the Wilcoxon rank sum test.

**Construction and validation of a predictive nomogram**

Nomogram was structured combining all independent prognostic factors from the previous step employing rms, foreign, and survival R packages (https://CRAN.R-project.org/package=rms, https://CRAN.R-project.org/package=foreign). The calibration curves and ROC curves were used to evaluate the capability of calibration and discrimination of the nomogram, respectively.
Functional enrichment analysis
The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were conducted based on the DEGs between different risk groups using clusterProfiler R package (Yu et al., 2012).

RESULTS
Consensus clustering of FRGs associated with the OS and distinct immune cell infiltration
In following step, 437 tumor samples were clustered using the ConsensusClusterPlus R package after removing normal samples (Wilkerson & Hayes, 2010). Clustering was performed based on the expression levels of the 200 FRGs using the K-means clustering algorithm. Considering the stability of clustering, the $k = 5$ seemed to be an optimal clustering patterns from $k = 2$ to 9 according to the expression similarity of FRGs (Fig. 2A and 2B). Finally, the CRC patients in training group were clustered into five subtypes. There are significant differences in the OS among the five clusters ($P = 0.0455$, Fig. 2C). Subsequently, the abundance of 6 immune cells among five groups was also analyzed. The abundance of six immune cells, including B_cell, CD4_T cell, CD8_T cell, Neutrophil, Macrophage and Dendritic, was downloaded from the TIMER website (Li et al., 2017). The ImmuneScore and StromalScore were calculated by ESTIMATE algorithm to estimate the infiltration levels of immunes and stromal cells in CRC (Yoshihara et al., 2013). The results showed that there are markedly different abundance of immune cells, PD1 and PD-L1 mRNA among five clusters (Figs. 2D–2M).

Identification of prognosis-related DEGs
A total of 165 DEGs between tumor and normal tissues, including 101 up-regulated and 64 down-regulated genes, were identified (Fig. 3A). Functional enrichment analysis was applied to explore the functions of these DEGs more comprehensively. The top enriched GO terms of these 165 DEGs were enriched in several basic biological processes related to extracellular stress and energy metabolism, including cellular response to chemical stress, oxidative stress, and nutrient levels and reactive oxygen species metabolic process (Fig. 3B). KEGG analysis found that these DEGs were mainly related to ferroptosis, autophagy, cellular senescence and CRC (Fig. 3C).

Univariate Cox regression analysis showed there were 13 genes with prognostic value in 200 FRGs. Finally, there were 10 FRGs associated with both differentially expressed and prognostic value by Veen analysis (Figs. 3D–3F). A protein protein interaction (PPI) network based on these genes is presented in Fig. 3G, indicating that SLC2A3, ATG7, NOX4 and TP63 were the hub genes. The correlation of these shared genes is shown in Fig. 3H. Moreover, the genetic alteration patterns of these risk-related genes were also explored to completely understand their contribution to CRC using the cBioPortal (Gao et al., 2013) (Fig. 3I).

Establishment a prognostic risk signature
Nextly, the selected 10 FRGs were recruited into LASSO Cox regression analysis. LASSO coefficient spectrum of each gene is illustrated in Fig. 4A. The optimal parameter (lambda)
was selected based on 10-time cross-validation in the LASSO model (Fig. 4B). Finally, all the 10 FRGs were included to establish the optimal prognostic risk signature. Consequently, a risk signature comprising 10 genes was developed. As shown in Fig. 4C, risk coefficient of each FRGs was calculated in the optimal model. The genes with coefficient <1, namely ATG7 and PGD, are considered as tumour suppressor genes, while the gene with coefficient >1, namely ATP6V1G2, DRD4, DUOX1, JDP2, NOX4, SLC2A3, TP63 and VEGFA, are regarded as oncogenes. The risk score of each patient is computed by the following formula both in TCGA and GEO cohorts. Risk score = \(-0.578*\text{ATG7 mRNA}\) + \(0.128*\text{ATP6V1G2 mRNA}\) + \(0.282*\text{DRD4 mRNA}\) + \(0.101*\text{DUOX1 mRNA}\) + \(0.379*\text{JDP2}\) + \(0.098*\text{NOX4 mRNA}\) + \(-0.150*\text{PGD}\) + \(0.103*\text{SLC2A3}\) + \(0.039*\text{TP63 mRNA}\) + \(0.038*\text{VEGFA mRNA}\).
Figure 3  Identification of prognosis-related key FRGs in CRC. (A) Volcano map of DEGs between normal and tumour tissues. Red represented up-regulated genes and green represented down-regulated genes. (B, C) GO and KEGG pathway enrichment analysis of these 165 DEGs. (D) Venn diagram for the shared genes between prognosis-related FRGs and DEGs. (E) The result of the univariate Cox regression analysis of these shared genes. (F) Heatmap of these shared genes. (G) Protein protein interaction (PPI) network of these genes. (H) The correlation between these DEGs. (I) The genetic alteration patterns of these key genes using cBioPortal.

Full-size DOI: 10.7717/peerj.11745/fig-3

Figure 4  Establishment of the risk signature. (A) A LASSO coefficient profile of the 10 genes. (B) Selection of the optimal parameters in the model by 10-fold cross-validation. (C) The coefficient of each FRGs in the final signature. LASSO, Least absolute shrinkage and selection operator.

Full-size DOI: 10.7717/peerj.11745/fig-4
Prognostic performance of the risk signature in training and validation cohorts

The patients were stratified into low- and high-risk groups based on the median value of risk score. The Kaplan–Meier survival curves indicated the patients with low risk score significantly were favorable OS than patients with high score both in TCGA and GEO cohorts (Figs. 5A–5C). The AUCs for 1-, 3-, and 5-year OS were 0.7632, 0.7411 and 0.7581 in TCGA cohort, respectively (Fig. 5D). The AUCs for 1-, 3-, and 5-year OS were 0.5756, 0.5924 and 0.5851 in the GEO GSE39582 cohort, respectively (Fig. 5E). The AUCs for 1-, 3-, and 5-year OS were 0.5967, 0.5744 and 0.5415 in the GEO GSE17538 cohort, respectively (Fig. 5F). Principal component analysis (PCA) showed that the CRC patients with high-risk could be distinguished effectively from low-risk patients using this risk signature in both training and validation sets (Figs. 5G–5I). Heatmap was used to display mRNA expression of these 10 risk-related genes. The genes with coefficient <1, like ATG7 and PGD, were more likely to have a high expression in patients with low-risk. While the patients in high-risk group were more likely to express the genes with coefficient >1, including DRD4, DUOX1, JDP2, NOX4, SLC2A3 and VEGFA (Figs. 5J, 5K and 5L).

The risk signature is an independent prognostic factor

The risk score based on the ten-FRGs was indicated as an independent prognostic factor in TCGA cohort (HR = 4.886, 95% CI [3.253–7.338], P<0.001, Fig. 6A), in GSE39582 cohort (HR = 1.885, 95% CI [1.153–3.0814]; P = 0.012, Fig. 6C) and in GSE17538 cohort (HR = 2.782, 95% CI [1.091–7.090]; P = 0.032, Fig. 6E) by univariate Cox analysis. Meanwhile, the risk score was also significantly correlated with OS in TCGA cohort (HR = 5.791, 95% CI [3.470–9.666]; P<0.001, Fig. 6B), in the GSE39582 cohort (HR = 1.698, 95% CI [1.007–2.864]; P = 0.047, Fig. 6D) and in the GSE17538 cohort (HR = 3.487, 95% CI [1.390–8.748]; P = 0.008, Fig. 6F) by multivariate Cox analysis.

Relationships between the risk score and clinicopathological features

The results showed that the risk score was independent with age (P = 0.8321, Fig. 7A) and gender (P = 0.6043, Fig. 7B). It was discovered that the risk score was correlated with pathological features in CRC. The risk score in stage III + IV patients was higher than those in stage I + II (P = 0.0133, Fig. 7C). The same results were obtained in other groups, including pT stage (T3 + T4 vs. T1 + T2, P = 0.0120, Fig. 7D), pM stage (M1 vs. M0, P = 0.0002, Fig. 7E) and pN stage (N1 + N2 vs. N0, P = 0.0187, Fig. 7F).

In addition, the relationship between risk score and cancer stem cells (CSCs) characteristics was also investigated in this study. The mRNA expression-based stemness index (mRNAsi) is widely used to evaluate stem cell characteristics of tumor cells. In this study, the mRNAsi of each CRC patient in TCGA cohort was downloaded from previous study of Malta et al. (2018). It was clear that the patients in low-risk group usually have higher stem cell characteristics, including mRNAsi (P < 0.0001, Fig. 7G), CD133 mRNA (P = 0.0473, Fig. 7H), CD166 mRNA (P = 0.0245, Fig. 7I) and CD44 mRNA (P = 0.0093, Fig. 7J).

The results of subgroup survival analysis indicated that the risk signature remains an independent prognostic factor in age (age ≥ 65 or <65, Figs. 6K and 6L), gender (male
or female, Figs. 6M and 6N), tumor stage (III + IV, Fig. 6O), T stage (T3 + T4, Fig. 6P), M stage (M0 and M1, Figs. 6Q and 6R) and N stage subgroups (N0 and N1+N2, Figs. 6S and 6T). It is obvious that the low-risk patients present markedly longer OS than high-risk patient in any clinicopathological subgroups.

**Integrated a prognostic nomogram by combining risk signature and clinicopathological features**

Nomogram is a powerful visualization tool in clinical practice for calculation individual risk value by integrating multiple factors. In this study, the nomogram containing four factors, namely age, gender, disease stage and risk score, was established for predicting the OS in CRC patients. A certain score is assigned to each factor based on its contribution to OS. Each patient would achieve a total point from the nomogram which is significantly
negatively correlated with the OS of the patient (Fig. 8A). The ROC curves indicated that the nomogram had powerful clinical application value with the AUCs of 0.8512 at 1 year, 0.8630 at 3 years and 0.8834 at 5 years in training set (Fig. 8B). Furthermore, the calibration plots suggest that the predictive probability of the nomogram match well with actual observation probability (Fig. 8C).

In validation set, the AUCs of ROC curves were 0.7765 at 1 year, 0.7319 at 3 years and 0.7077 at 5 years in the GSE39582 cohort (Fig. 8D). The AUCs of ROC curve were 0.8322 at 1 year, 0.7937 at 3 years and 0.8056 at 5 years in the GSE17538 set (Fig. 8F). Meanwhile, the calibration plots both show that the actual observed probability agrees with predictive value of nomogram (Figs. 8E and 8G).
Figure 7  Relationships between the risk score and clinicopathological features. (A)(B) The risk score was independent with age and gender. (C–F) The risk score was correlated with pathological features in CRC, including tumour stage, pT stage, pM stage and pN stage. (G–J) The patients in low-risk group with higher stem cell characteristics, including mRNAsi, CD133, CD166 and CD44 mRNA. (K–T) The result of subgroup survival analysis.
Figure 8  Integrated prognostic nomogram by combining risk signature and clinicopathological features. (A) A genomic-clinicopathologic nomogram predicting 1-, 3-, and 5-year OS of CRC. (B)-(C) Time-dependent ROC curves and calibration plots of the combining nomogram in training set. (D)-(E) Time-dependent ROC curves and calibration plots of the combining nomogram in the GSE39582 cohort. (F)-(G) Time-dependent ROC curves and calibration plots of the combining nomogram in the GSE17538 cohort. OS, overall survival.

High ferroptosis risk score indicates an inhibitory immune microenvironment

The abundance of 22 immune cells was calculated by the CIBERSORT algorithm (Newman et al., 2019). There were different immune landscapes between high and low risk groups. The distribution patterns of 22 immune cells differed markedly between the high- and low-risk group (Figs. 9A and 9B). The difference analysis showed that T cells CD8 ($P = 0.012$), mast cells activated ($P = 0.027$), monocytes ($P = 0.015$), M0 ($P = 0.002$) and M2-like macrophages ($P = 0.015$) were enriched in the high-risk group distinctly, while the patients in low-risk group had higher level of T cells CD4 memory resting ($P = 0.003$), T
cells CD4 memory activated ($P = 0.002$), dendritic cells activated ($P = 0.014$), mast cells resting ($P = 0.015$) and neutrophils ($P = 0.009$) (Fig. 9C).

As the markers of T cell exhaustion, immune checkpoints usually present an immunosuppressive effect in tumorigenesis and immune evasion. This study indicated the risk score was positively correlated with immune checkpoints, including PD1, LAG3 and VSIR (both $P < 0.05$, Figs. 9D–9F). These results reveal that patients with high ferroptosis risk score are more inclined to form a suppressive immune microenvironment via upregulating immune checkpoints and increasing the infiltration level of suppressive immune cells.

**Functional annotation of the risk signature**

The DEGs between the high- and low-risk groups were used to elucidate the molecular mechanisms by GO enrichment and KEGG pathway analysis in TCGA cohort. The results of GO enrichment analysis showed that the high-risk group is significantly enrich in energy metabolism processes, including mitochondrial gene expression, mitochondrial matrix, mitochondrial inner membrane, mitochondrial protein complex and ATPase activity (Fig. 10A). KEGG pathways enrich in the high-risk group including thermogenesis, fatty acid metabolism, and amino sugar and nucleotide sugar metabolism (Fig. 10B).

**DISCUSSION**

Ferroptosis is an iron- and reactive oxygen species (ROS)-dependency form of cell death different from other cell death and contributes to suppress tumor growth and enhancing chemosensitivity (Liang et al., 2019). Since the term of ferroptosis was raised, much effort has been devoted to its cellular mechanisms and signaling pathways. However, prognostic power of a FRGs panel for CRC has not been fully characterized. In this study, the two...
hundred FRGs were systematically investigated in terms of prognostic value, roles in the immune microenvironment and potential regulatory mechanisms in CRC. The majority of FRGs (165/200) were diversely expressed between normal and tumor tissues, and a total of 10 out of these genes were proved to have significantly prognostic value. This ten-FRGs risk signature was better at distinguishing patients with high risk from low risk. Furthermore, we found that the patients in high-risk group were inclined to have a suppressive immune microenvironment and lower stemness features. Meanwhile, a genomic-clinicopathologic nomogram has been developed in TCGA cohort and validated in two external cohorts. Notably, the nomogram showed superiority compared with common clinical indicators, such as TNM stage.

The ten FRGs integrated into this risk signature could be roughly classified into three categories according to the FerrDb, including driver genes (ATG7, DUOX1, NOX4 and PGD), suppressors genes (TP63) and markers genes (ATP6V1G2, DRD4, JDP2, SLC2A3 and VEGFA). ATG7 and PGD may act as protecting genes whereas ATP6V1G2, DRD4, DUOX1, JDP2, NOX4, SLC2A3, TP63 and VEGFA are the major driving force of tumorigenesis and progression. ATG7 is initially found in the process of autophagy, which participated in the formation of microtubule-associated protein 1 light chain (MAP1LC3) and the subsequent lipidation process, as a key step in the formation of autophagosomes (Nakamura & Yoshimori, 2017). More studies have shown that there is a close connection between autophagy and ferroptosis (Zhou et al., 2020). Iron accumulation and lipid peroxidation produced by excessive autophagy and lysosomal activity can accelerate ferroptosis (Park & Chung, 2019). Knockout of ATG7 could suppress ferroptosis through restraining Erastin-induced ferritin degradation, lipid peroxidation and iron accumulation (Hou et al., 2016). DRD4 is a member of the dopamine receptor family and involved in the positive regulation of tumor behaviors, such as tumor cell proliferation, invasion and
metastasis. Erastin, an important inducer of ferroptosis, can be blocked by DRD4 leading to ferroptosis inhibition (Wang et al., 2019b).

Although the mechanism of ferroptosis has been deeply explored, the interaction between ferroptosis and tumor immune microenvironment remains unclear. It is reported that ferroptotic cancer cells can drive tumor-associated macrophage polarization through releasing oncogenic KRAS protein (Dai et al., 2020). There is a complex highly synergistic effect between ferroptosis and T cell immunity or cancer immunotherapy. Tumor necrosis factor and interferon gamma released by CD8+ T cells are the driving factors of ferroptosis (Wang et al., 2019a). Tumor clearance function of CD8+ T cells in the tumor microenvironment could be restored and enhanced by cancer immunotherapy. Mechanistically, immunotherapy-activated CD8+ T cells could enhance lipid peroxidation and iron accumulation which activated ferroptosis. Meanwhile, activated ferroptosis was also capable to enhance the anti-tumor effect from immunotherapy (Wang et al., 2019a). In addition, studies have shown that CD8+ T cells can increase the sensitivity of tumor cells to radiotherapy and PD-L1/PD-1 or CTLA-4 blocking therapy by promoting ferroptosis (Lang et al., 2019). In this study, the high-risk group has higher abundance of monocytes and M2-like macrophages. Besides, the risk score is significantly positively correlated with the expression level of immune checkpoints. These mean that patients in the high-risk group tend to have a worse prognosis because they were more likely to experience immune evasion and cancer-promoting immune microenvironment. These new findings offer promising prospects for increasing antitumor effects by leveraging pro-ferroptotic activity of the immune system.

Based on the DEGs between high and low risk groups, functional analysis revealed that the biological processes and pathways about energy metabolism was markedly enriched. Tumor cells require higher levels of iron and energy metabolism (especially lipid metabolism) than normal cells to meet their rapidly proliferating needs, making them more susceptible to ferroptosis (Li & Li, 2020). There is now substantial research showing that lipid metabolism has a significant role in tumorigenesis, development, metastasis, chemoresistance and radioresistance (Rohrig & Schulze, 2016; Moloney & Cotter, 2018). Ferroptosis is a special form of programmed cell death characterized by iron-dependent ROS accumulation. ROS is a by-product of aerobic metabolism, to which lipid peroxide provides the most prominent source offering important basis for ferroptosis (Gaschler & Stockwell, 2017; Yang & Stockwell, 2016). In this study, the CSCs characteristics between different risk groups were also explored. At the cellular level, CSCs serve as an important mechanism leading to the heterogeneity and chemoresistance of CRC (Nunes et al., 2018; Li et al., 2019). Therefore, targeting CSCs has a great prospect for reversing chemoresistance. It can increase the sensitivity of colorectal CSCs to cisplatin treatment via promoting ferroptosis by knocking out or inhibiting SLC7A11 (Xu et al., 2020). In this study, the patients in low-risk group were inclined to have higher stemness feature, suggesting they are more likely to benefit from targeted CSCs therapy.
CONCLUSION

We for the first time profiled the prognostic value of FRGs in CRC. Two hundred FRGs were screened and ten key prognostic genes were identified, which played a crucial function in the progression and might become the potential therapeutic targets for CRC. More importantly, a robust prognostic genomic-clinico-pathologic nomogram could be used as an individualized and more accurate survival prediction tool than the TNM stage alone. Overall, this integrated study based on three CRC cohorts contribute to a deeper understanding of CRC biological behavior and potential interventions in the perspective of ferroptosis.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
The present study was supported by the Wu Jieping Medical Foundation (320.2710.1855). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
The Wu Jieping Medical Foundation: 320.2710.1855.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Chao Yang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Shuoyang Huang performed the experiments, prepared figures and/or tables, and approved the final draft.
• Fengyu Cao analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Yongbin Zheng conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The raw transcriptome data of this study are available in the TCGA database (TCGA-COAD/READ cohorts)(https://portal.gdc.cancer.gov/) and GEO: GSE39582 and GSE17538.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.11745#supplemental-information.
REFERENCES

Carr PR, Weigl K, Jansen L, Walter V, Erben V, Chang-Claude J, Brenner H, Hoffmeister M. 2018. Healthy lifestyle factors associated with lower risk of colorectal cancer irrespective of genetic risk. Gastroenterology 155:1805–1815 DOI 10.1053/j.gastro.2018.08.044.

Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T. 2020. Combinative treatment of beta-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics 10:5107–5119 DOI 10.7150/thno.44705.

Dai E, Han L, Liu J, Xie Y, Kroemer G, Klionsky DJ, Zeh HJ, Kang R, Wang J, Tang D. 2020. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy 16:2069–2083 DOI 10.1080/15548627.2020.1714209.

Dekker E, Tanis PJ, Vleugels J, Kasi PM, Wallace MB. 2019. Colorectal cancer. Lancet 394:1467–1480 DOI 10.1016/S0140-6736(19)32319-0.

Dong W, Tan Y, Qin Q, Yang B, Zhu Q, Xu L, Liu Z, Song E, Song Y. 2019. Polybrominated diphenyl ethers quinone induces NCOA4-mediated ferritinophagy through selectively autophagic degradation of ferritin. Chemical Research in Toxicology 32:2509–2516 DOI 10.1021/acs.chemrestox.9b00350.

Engebretsen S, Bohlin J. 2019. Statistical predictions with glmnet. Clinical Epigenetics 11:123 DOI 10.1186/s13148-019-0730-1.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling 6(269):pl1 DOI 10.1126/scisignal.2004088.

Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. 2016. Ferroptosis is an autophagic cell death process. Cell Research 26:1021–1032 DOI 10.1038/cr.2016.95.

Gaschler MM, Stockwell BR. 2017. Lipid peroxidation in cell death. Biochemical and Biophysical Research Communications 482:419–425 DOI 10.1016/j.bbrc.2016.10.086.

Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307–315 DOI 10.1093/bioinformatics/btg405.

Guo J, Xu B, Han Q, Zhou H, Xia Y, Gong C, Dai X, Li Z, Wu G. 2018. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Research and Treatment 50:445–460 DOI 10.4143/crt.2016.572.

Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HR, Kang R, Tang D. 2016. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12:1425–1428 DOI 10.1080/15548627.2016.1187366.

Hu T, Li Z, Gao CY, Cho CH. 2016. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World Journal of Gastroenterology 22:6876–6889 DOI 10.3748/wjg.v22.i30.6876.
Kang R, Kroemer G, Tang D. 2019. The tumor suppressor protein p53 and the ferroptosis network. *Free Radical Biology and Medicine* **133**:162–168 DOI 10.1016/j.freeradbiomed.2018.05.074.

Keum N, Giovannucci E. 2019. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nature Reviews Gastroenterology & Hepatology* **16**:713–732 DOI 10.1038/s41575-019-0189-8.

Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, Saripalli AL, Kryczek I, Wei S, Szleiga W, Vatan L, Stone EM, Georgiou G, Cieslik M, Wahl DR, Morgan MA, Chinnaiyan AM, Lawrence TS, Zou W. 2019. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. *Cancer Discovery* **9**:1673–1685 DOI 10.1158/2159-8290.CD-19-0338.

Li N, Babaie-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, Tulchinsky E, Vries R, Kerr D, Pan Y, He Y, Bates DO, Tomlinson I, Clevers H, Nateri AS. 2019. An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. *Oncogenesis* **8**(3) DOI 10.1038/s41389-019-0125-3.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. 2017. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Research* **77**:e108–e110 DOI 10.1158/0008-5472.CAN-17-0307.

Li D, Li Y. 2020. The interaction between ferroptosis and lipid metabolism in cancer. *Signal Transduction and Targeted Therapy* **5**(1):108 DOI 10.1038/s41392-020-00216-5.

Liang C, Zhang X, Yang M, Dong X. 2019. Recent progress in ferroptosis inducers for cancer therapy. *Advanced Materials* **31**:e1904197 DOI 10.1002/adma.201904197.

Malfa GA, Tomasello B, Acquaviva R, Genovese C, La Mantia A, Cammarata FP, Ragusa M, Renis M, Di Giacomo C. 2019. Betula etnensis Raf. (Betulaceae) extract induced HO-1 expression and ferroptosis cell death in human colon cancer cells. *International Journal of Molecular Sciences* **20**(11):2723 DOI 10.3390/ijms20112723.

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwinska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wigler M, M. 2018. Machine learning identifies stemness features associated with oncogenic dedifferentiation. *Cell* **173**:338–354 DOI 10.1016/j.cell.2018.03.034.

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Filomognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fuji H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Cirillo MR, Aquilano K, Chen S, Mohamed SI, Keith WN, Bilisland A, Halicka D, Noowsheen S, Azmi AS. 2015. Broad targeting of resistance to apoptosis in cancer. *Seminars in Cancer Biology* **35 Suppl**:S78–S103 DOI 10.1016/j.semcancer.2015.03.001.
Moloney JN, Cotter TG. 2018. ROS signalling in the biology of cancer. *Seminars in Cell & Developmental Biology* 80:50–64 DOI 10.1016/j.semcdb.2017.05.023.

Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, Li B. 2019. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. *Journal of Hematology & Oncology* 12(1):34 DOI 10.1186/s13045-019-0720-y.

Nakamura S, Yoshimori T. 2017. New insights into autophagosome-lysosome fusion. *Journal of Cell Science* 130:1209–1216 DOI 10.1242/jcs.196352.

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA. 2019. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nature Biotechnology* 37:773–782 DOI 10.1038/s41587-019-0114-2.

Nunes T, Hamdan D, Leboeuf C, El BM, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. 2018. Targeting cancer stem cells to overcome chemoresistance. *International Journal of Molecular Sciences* 19(12):4036 DOI 10.3390/ijms19124036.

Oines M, Helsingren LM, Bretthauer M, Emilsson L. 2017. Epidemiology and risk factors of colorectal polyps. *Best Practice & Research: Clinical Gastroenterology* 31:419–424 DOI 10.1016/j.bpg.2017.06.004.

Park E, Chung SW. 2019. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. *Cell Death & Disease* 10:822 DOI 10.1038/s41419-019-2064-5.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43:e47 DOI 10.1093/nar/gkv007.

Rohrig F, Schulze A. 2016. The multifaceted roles of fatty acid synthesis in cancer. *Nature Reviews Cancer* 16:732–749 DOI 10.1038/nrc.2016.89.

Sharma P, Shimura T, Banwait JK, Goel A. 2020. Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of beta-catenin/Wnt-signaling pathways in colorectal cancer. *Carcinogenesis* 41:1385–1394 DOI 10.1093/carcin/bgaa090.

Tang M, Chen Z, Wu D, Chen L. 2018. Ferritinophagy/ferroptosis: iron-related newcomers in human diseases. *Journal of Cellular Physiology* 233:9179–9190 DOI 10.1002/jcp.26954.

Tokunaga R, Nakagawa S, Sakamoto Y, Nakamura K, Naseem M, Izumi D, Kosumi K, Taki K, Higashi T, Miyata T, Miyamoto Y, Yoshida N, Baba H, Lenz HJ. 2020. 12-Chemokine signature, a predictor of tumor recurrence in colorectal cancer. *International Journal of Cancer* 147:532–541 DOI 10.1002/ijc.32982.

Wang W, Green M, Choi JE, Gijon M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, Xia H, Zhou J, Li G, Li J, Li W, Wei S, Vatan L, Zhang H, Szeliga W, Gu W, Liu R, Lawrence TS, Lamb C, Tanno Y, Cieslik M, Stone E, Georgiou G, Chan TA, Chinnaiyan A, Zou W. 2019a. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. *Nature* 569:270–274 DOI 10.1038/s41586-019-1170-y.
Wang X, Wang ZB, Luo C, Mao XY, Li X, Yin JY, Zhang W, Zhou HH, Liu ZQ. 2019b. The prospective value of dopamine receptors on bio-behavior of tumor. *Journal of Cancer* 10:1622–1632 DOI 10.7150/jca.27780.

Wang J, Yu S, Chen G, Kang M, Jin X, Huang Y, Lin L, Wu D, Wang L, Chen J. 2020. A novel prognostic signature of immune-related genes for patients with colorectal cancer. *Journal of Cellular and Molecular Medicine* 24:8491–8504 DOI 10.1111/jcmm.15443.

Weiser MR. 2018. AJCC 8th edition: colorectal cancer. *Annals of Surgical Oncology* 25:1454–1455 DOI 10.1245/s10434-018-6462-1.

Wilkerson MD, Hayes DN. 2010. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. *Bioinformatics* 26:1572–1573 DOI 10.1093/bioinformatics/btq170.

Xu X, Zhang X, Wei C, Zheng D, Lu X, Yang Y, Luo A, Zhang K, Duan X, Wang Y. 2020. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis. *European Journal of Pharmaceutical Sciences* 152:105450 DOI 10.1016/j.ejps.2020.105450.

Yang WS, Stockwell BR. 2016. Ferroptosis: death by lipid peroxidation. *Trends in Cell Biology* 26:165–176 DOI 10.1016/j.tcb.2015.10.014.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. 2013. Inferring tumour purity and stromal and immune cell admixture from expression data. *Nature Communications* 4:2612 DOI 10.1038/ncomms3612.

Yu G, Wang LG, Han Y, He QY. 2012. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omnics-a Journal of Integrative Biology* 16:284–287 DOI 10.1089/omi.2011.0118.

Zhou N, Bao J. 2020. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. *Database* 2020:baaa021 DOI 10.1093/database/baa021.

Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. 2020. Ferroptosis is a type of autophagy-dependent cell death. *Seminars in Cancer Biology* 66:89–100 DOI 10.1016/j.semcancer.2019.03.002.